Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
91.37
+1.05 (+1.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biomarin Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
The 3 Best Biotech Stocks to Buy in May 2024
May 09, 2024
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.
Via
InvestorPlace
Citi Just Cut Its Price Target on These 3 Stocks
May 03, 2024
Reviewing analyst downgrades may help safeguard investment portfolios amid market uncertainty and Citi price target cuts.
Via
InvestorPlace
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
April 30, 2024
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Via
Chartmill
4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
April 27, 2024
Opportunistic investors can still find bargains, even with the Nasdaq Composite up 49% since the start of 2023.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)
April 25, 2024
Via
Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
April 25, 2024
Many fortunes have been made with a fortuitous investment in a biotech stock at the right time. That time might be now.
Via
InvestorPlace
Looking Into Biomarin Pharmaceutical's Recent Short Interest
April 03, 2024
Via
Benzinga
The Latest Analyst Ratings For Biomarin Pharmaceutical
February 23, 2024
Via
Benzinga
Recap: Biomarin Pharmaceutical Q4 Earnings
February 22, 2024
Via
Benzinga
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 25, 2024
Via
Benzinga
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
April 24, 2024
BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 24, 2024
Via
Benzinga
Decoding 8 Analyst Evaluations For Biomarin Pharmaceutical
January 30, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
December 21, 2023
Via
Benzinga
Don't overlook NASDAQ:BMRN—a stock with solid growth prospects and a reasonable valuation.
April 08, 2024
Investors seeking growth at a reasonable cost should explore BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN).
Via
Chartmill
While growth is established for NASDAQ:BMRN, the stock's valuation remains reasonable.
March 18, 2024
Despite its growth, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) remains within the realm of affordability.
Via
Chartmill
4 Extraordinary Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
March 16, 2024
Although the Nasdaq Composite is galloping to record highs, amazing deals among growth stocks can still be uncovered.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
February 26, 2024
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
Via
Chartmill
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
Via
InvestorPlace
Earnings Outlook For Biomarin Pharmaceutical
October 31, 2023
Via
Benzinga
3 No-Brainer Stocks to Buy With $200 Right Now
February 07, 2024
A reasonably small amount of money can go a long way when it's put to work in innovative, industry-leading businesses.
Via
The Motley Fool
4 Marvelous Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
January 20, 2024
A greater than 7% decline in the Nasdaq Composite from its record high signals that opportunistic investors can still find bargains.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
January 10, 2024
Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month.
Via
InvestorPlace
4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
December 02, 2023
An 11% decline in the Nasdaq Composite over the past two years is an open invitation for opportunistic growth investors to go shopping.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
November 09, 2023
Unveil the resilience of biotech stocks as they outsmart market trends and champion the race for tomorrow's treatments.
Via
InvestorPlace
3 Promising Biotech Stocks Flying Under the Radar
November 08, 2023
Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.
Via
InvestorPlace
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
November 07, 2023
The company's recently FDA-approved gene therapy is struggling to gain traction.
Via
Investor's Business Daily
Datadog, Tripadvisor, Myriad Genetics, Planet Fitness And Other Big Stocks Moving Higher On Tuesday
November 07, 2023
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining around 50 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
November 04, 2023
A 19% decline in the Nasdaq Composite over the past two years represents an ideal time for opportunistic long-term investors to go shopping for bargains.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today?
October 27, 2023
In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.